SCHEMBL6738504

SCHEMBL6738504

N#CCNC(=O)C(CS(=O)(=O)Cc1ccccc1)NC(=O)c1cc2ccccc2o1

nearest known ligand 0.55

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CTSS P25774 9/20 0.55
CTSB P07858 8/20 0.55
CTSL P07711 4/20 0.53
TAS1R3 Q7RTX0 3/20 0.52
TAS1R1 Q7RTX1 3/20 0.52
MEN1 O00255 1/20 0.52
NPC1 O15118 1/20 0.52
RAB9A P51151 1/20 0.52
KMT2A Q03164 1/20 0.52
ALDH1A1 P00352 3/20 0.49
LMNA P02545 1/20 0.48
THRB P10828 1/20 0.48
TP53 P04637 1/20 0.48
HPGD P15428 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
CTSK P43235 3/20 0.47
CTSF Q9UBX1 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6738509 1.00 CTSS (0.55) CTSSCTSBCTSLTAS1R3TAS1R1
SCHEMBL6744256 0.83 CTSL (0.72) CTSSCTSBCTSLALDH1A1CTSK
SCHEMBL6744264 0.83 CTSL (0.72) CTSSCTSBCTSLALDH1A1CTSK
SCHEMBL6738426 0.82 CTSS (0.77) CTSSCTSBCTSLCTSK
SCHEMBL6738423 0.82 CTSS (0.77) CTSSCTSBCTSLCTSK
SCHEMBL6742242 0.82 CTSB (0.64) CTSSCTSBCTSLCTSK
SCHEMBL6742241 0.82 CTSB (0.64) CTSSCTSBCTSLCTSK
SCHEMBL5528180 0.81 MEN1 (0.53) CTSSCTSBCTSLTAS1R3TAS1R1
SCHEMBL5528176 0.81 MEN1 (0.53) CTSSCTSBCTSLTAS1R3TAS1R1
SCHEMBL6738512 0.81 SMN1; SMN2 (0.54) TAS1R3TAS1R1MEN1NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040014796-A1 Novel compounds and compositions as cathepsin S inhititors AXYS PHARMACEUTICALS, INC. 2004-01-22 US disclosed
US-6492362-B1 Compounds and compositions as cathepsin S inhibitors AXYS PHARMACEUTICALS, INC. 2002-12-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040014796-A1 Novel compounds and compositions as cathepsin S inhititors CTSS, CTSB, CTSE CTSS 1/4885CTSB 2/4885CTSL 10/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.